After MLC in Kit-M-treated AML patients’ samples, we confirmed preliminary data by showing increased IFNγ production by T cell subtypes (e.g., ß7-expressing T, Tnon-naïve, Tem/eff and Tcm) in Kit-M-treated WB compared to controls (Supplementary Figure S5A) [17]. The gene discussed is KIT; the disease is acute myeloid leukemia.